System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review Epublish 45 citations

PubMed: 35408796 DOI: 10.3390/ijms23073439

The Role of Advanced Glycation End Products and Its Soluble Receptor in Kidney Diseases.

Int J Mol Sci 23(7)

Authors: Mieke Steenbeke, Reinhart Speeckaert, Stéphanie Desmedt, Griet Glorieux, Joris R Delanghe, Marijn M Speeckaert

Affiliations

  • Nephrology Unit, Department of Internal Medicine and Pediatrics, Ghent University Hospital, 9000 Ghent, Belgium.
  • Department of Dermatology, Ghent University Hospital, 9000 Ghent, Belgium.
  • Research Foundation Flanders, 1000 Brussels, Belgium.
  • Department of Diagnostic Sciences, Ghent University, 9000 Ghent, Belgium.

Abstract

Patients with chronic kidney disease (CKD) are more prone to oxidative stress and chronic inflammation, which may lead to an increase in the synthesis of advanced glycation end products (AGEs). Because AGEs are mostly removed by healthy kidneys, AGE accumulation is a result of both increased production and decreased kidney clearance. On the other hand, AGEs may potentially hasten decreasing kidney function in CKD patients, and are independently related to all-cause mortality. They are one of the non-traditional risk factors that play a significant role in the underlying processes that lead to excessive cardiovascular disease in CKD patients. When AGEs interact with their cell-bound receptor (RAGE), cell dysfunction is initiated by activating nuclear factor kappa-B (NF-κB), increasing the production and release of inflammatory cytokines. Alterations in the AGE-RAGE system have been related to the development of several chronic kidney diseases. Soluble RAGE (sRAGE) is a decoy receptor that suppresses membrane-bound RAGE activation and AGE-RAGE-related toxicity. sRAGE, and more specifically, the AGE/sRAGE ratio, may be promising tools for predicting the prognosis of kidney diseases. In the present review, we discuss the potential role of AGEs and sRAGE as biomarkers in different kidney pathologies.

MeSH

Kidney Diseases, Cells, Glycation End Products, Advanced

Cited by